Muhannad Abu-Remaileh

5PUBLICATIONS
13CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 28, 2026
Publisher Correction: argeting of HIF2-driven cachexia in kidney cancer.

Muhannad Abu-Remaileh, Laura A Stransky, Nikita Bhalerao

|Nov 29, 2025
Targeting of HIF2-driven cachexia in kidney cancer.

Muhannad Abu-Remaileh, Laura A Stransky, Nikita Bhalerao

|Sep 18, 2025
HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors.

Muhannad Abu-Remaileh, Laura A Stransky, Nikita Bhalerao

|Sep 25, 2024
Total loss of VHL gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity.

Muhannad Abu-Remaileh, Nicole S Persky, Yenarae Lee

|Dec 26, 2022
Loss of tumor suppressor WWOX accelerates pancreatic cancer development through promotion of TGFβ/BMP2 signaling.

Hussam Husanie, Muhannad Abu-Remaileh, Kian Maroun

Pageof 1